On September 11, 2007, Sepracor signed a marketing deal with British pharmaceutical company GlaxoSmithKline for the rights to sell Eszopiclone (under the name Lunivia rather than Lunesta) in Europe.[22] Sepracor was expected to receive approximately 155 million dollars if the deal went through.


However, on average, Lunesta patients still met criteria for insomnia and reported no clinically meaningful improvement in next-day alertness or functioning.

so the study shows it really does not work, except to poison your liver.

http://en.wikipedia.org/wiki/Eszopiclone